Drugs / MGD020
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07217379 | Oct 2025 → Dec 2026 | HIV infectious disease | University of North Carolina, Chapel Hill | Suspended | No outcome recorded |
| Phase 1 | NCT05261191 | Sep 2022 → May 2024 | HIV infectious disease | MacroGenics | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MGD020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07217379 ↗ |
| Action | Deplete | “These DART molecules redirect CD3+ T lymphocytes to kill HIV-1-infected CD4+ T cells.” NCT05261191 ↗ |
| Modality | Other / unclassified | “MGD020 is a bispecific DART molecule” NCT05261191 ↗ |
| Route | Intravenous | “All participants will receive a total of 4 doses of MGD014/MGD020 at 300 mcg/kg administered as intravenous infusion.” NCT07217379 ↗ |